SG11201810927QA - Pd-l1-specific antibodies and methods of using the same - Google Patents
Pd-l1-specific antibodies and methods of using the sameInfo
- Publication number
- SG11201810927QA SG11201810927QA SG11201810927QA SG11201810927QA SG11201810927QA SG 11201810927Q A SG11201810927Q A SG 11201810927QA SG 11201810927Q A SG11201810927Q A SG 11201810927QA SG 11201810927Q A SG11201810927Q A SG 11201810927QA SG 11201810927Q A SG11201810927Q A SG 11201810927QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- control mab
- pct
- antibodies
- fragments
- Prior art date
Links
- 239000012634 fragment Substances 0.000 abstract 3
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 2
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000013642 negative control Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
CTINegative control mAb Clinical control mAb IC50 0.4909 0.1941 - 0.0 60000 40000 20000 0 0.001 0.01 0.1 1 10 I ogiAntagonisq, ugeml -J 100 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 January 2018 (04.01.2018) W I PO I PCT mu °million °nolo olon imio (10) International Publication Number WO 2018/005682 A2 (51) International Patent Classification: C07K 16/28 (2006.01) A61K 45/06 (2006.01) (21) International Application Number: PCT/US2017/039810 (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) 28 June 2017 (28.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/356,105 29 June 2016 (29.06.2016) US (71) Applicant: CHECKPOINT THERAPEUTICS, INC. [US/US]; 2 Gansevoort Street, 9th Floor, New York, NY 10014 (US). (72) Inventors: BELK, Jonathan; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, NH 03766 (US). SHARKEY, Nathan, J.; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, NH 03766 (US). GORELIK, Leonid; 69 Winston Road, Newton, MA 02459 (US). (74) Agent: VILLACORTA, Gilberto, M. et al.; Foley & Lard- ner LLP, 3000 K Street NW, Suite 600, Washington, DC 20007 (US). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, W O 20 18/005 68 2 A2 (54) Title: PD-Ll-SPECIFIC ANTIBODIES AND METHODS OF USING THE SAME is Clinical control mAb CTI-048 A Negative control mAb FIGURE 5 (57) : The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-Ll and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662356105P | 2016-06-29 | 2016-06-29 | |
PCT/US2017/039810 WO2018005682A2 (en) | 2016-06-29 | 2017-06-28 | Pd-l1-specific antibodies and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810927QA true SG11201810927QA (en) | 2019-01-30 |
Family
ID=60785529
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810927QA SG11201810927QA (en) | 2016-06-29 | 2017-06-28 | Pd-l1-specific antibodies and methods of using the same |
SG10202100100UA SG10202100100UA (en) | 2016-06-29 | 2017-06-28 | Pd-l1-specific antibodies and methods of using the same |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202100100UA SG10202100100UA (en) | 2016-06-29 | 2017-06-28 | Pd-l1-specific antibodies and methods of using the same |
Country Status (13)
Country | Link |
---|---|
US (2) | US10590199B2 (en) |
EP (1) | EP3478723A4 (en) |
JP (2) | JP7148414B2 (en) |
KR (2) | KR20190028716A (en) |
CN (1) | CN109641960A (en) |
AU (1) | AU2017290709A1 (en) |
BR (1) | BR112018076684A2 (en) |
CA (1) | CA3027204A1 (en) |
IL (2) | IL263611B (en) |
MX (1) | MX2018016183A (en) |
RU (1) | RU2749109C2 (en) |
SG (2) | SG11201810927QA (en) |
WO (1) | WO2018005682A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
EP3268392A2 (en) | 2015-03-13 | 2018-01-17 | CytomX Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
JP7148414B2 (en) * | 2016-06-29 | 2022-10-05 | チェックポイント セラピューティクス,インコーポレイテッド | PD-L1 specific antibodies and methods of using same |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
AU2018278327B2 (en) | 2017-06-01 | 2023-03-16 | Cytomx Therapeutics, Inc. | Activatable anti-pdl1 antibodies and methods of use thereof |
AU2019370094B2 (en) | 2018-10-31 | 2022-02-03 | Nantkwest, Inc. | Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells |
KR102207478B1 (en) * | 2019-03-13 | 2021-01-26 | 한국도로공사 | Tolling system using time information and operating method thereof |
AU2020261961B2 (en) | 2019-04-26 | 2022-07-07 | I-Mab Biopharma Co., Ltd. | Human PD-L1 antibodies |
AU2020281535A1 (en) | 2019-05-24 | 2022-01-27 | Merck Patent Gmbh | Combination therapies using CDK inhibitors |
CN113121686A (en) * | 2019-12-31 | 2021-07-16 | 迈威(上海)生物科技股份有限公司 | anti-PD-L1 antibody and application thereof |
TW202327595A (en) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | Combinations of azalactam compounds for the treatment of cancer |
WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
US7700739B2 (en) | 2005-06-30 | 2010-04-20 | Abbott Laboratories | IL-12/p40 binding proteins |
RS54271B1 (en) * | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
JP2009513147A (en) * | 2005-10-31 | 2009-04-02 | アメリカ合衆国 | Antibodies and immunotoxins targeting human glycoprotein NMB |
GB0914691D0 (en) | 2009-08-21 | 2009-09-30 | Lonza Biologics Plc | Immunoglobulin variants |
LT3279215T (en) * | 2009-11-24 | 2020-04-10 | Medimmune Limited | Targeted binding agents against b7-h1 |
CN103987405B (en) * | 2011-11-28 | 2017-03-29 | 默克专利股份公司 | Anti- PD L1 antibody and application thereof |
EP3553086A1 (en) * | 2012-05-31 | 2019-10-16 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind pd-l1 |
CA3139031A1 (en) * | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
TWI680138B (en) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
CN106029098A (en) | 2014-02-25 | 2016-10-12 | 免疫医疗公司 | Humanized RFB4 anti-CD22 antibody |
IL252295B2 (en) | 2014-12-19 | 2023-10-01 | Dana Farber Cancer Inst Inc | Chimeric antigen receptors and methods of use thereof |
EP3268392A2 (en) * | 2015-03-13 | 2018-01-17 | CytomX Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
BR112018013677A2 (en) * | 2016-01-11 | 2019-01-22 | Inhibrx Inc | multivalent and multispecific 41bb binding fusion proteins |
KR102523402B1 (en) * | 2016-06-14 | 2023-04-19 | 젠코어 인코포레이티드 | Bispecific Checkpoint Inhibitor Antibodies |
JP7148414B2 (en) * | 2016-06-29 | 2022-10-05 | チェックポイント セラピューティクス,インコーポレイテッド | PD-L1 specific antibodies and methods of using same |
JP2019526595A (en) * | 2016-09-09 | 2019-09-19 | ティージー セラピューティクス,インコーポレイテッド | Combination of anti-CD20 antibody, PI3 kinase-delta inhibitor and anti-PD-1 antibody or anti-PD-L1 antibody for treating blood cancer |
-
2017
- 2017-06-28 JP JP2018567904A patent/JP7148414B2/en active Active
- 2017-06-28 US US15/636,610 patent/US10590199B2/en active Active
- 2017-06-28 KR KR1020197002192A patent/KR20190028716A/en not_active Application Discontinuation
- 2017-06-28 SG SG11201810927QA patent/SG11201810927QA/en unknown
- 2017-06-28 RU RU2019102009A patent/RU2749109C2/en active
- 2017-06-28 SG SG10202100100UA patent/SG10202100100UA/en unknown
- 2017-06-28 EP EP17821178.5A patent/EP3478723A4/en active Pending
- 2017-06-28 BR BR112018076684-4A patent/BR112018076684A2/en unknown
- 2017-06-28 CN CN201780045033.XA patent/CN109641960A/en active Pending
- 2017-06-28 KR KR1020217041795A patent/KR102422411B1/en active IP Right Grant
- 2017-06-28 AU AU2017290709A patent/AU2017290709A1/en active Pending
- 2017-06-28 CA CA3027204A patent/CA3027204A1/en active Pending
- 2017-06-28 MX MX2018016183A patent/MX2018016183A/en unknown
- 2017-06-28 WO PCT/US2017/039810 patent/WO2018005682A2/en unknown
-
2018
- 2018-12-10 IL IL263611A patent/IL263611B/en active IP Right Grant
-
2020
- 2020-03-13 US US16/818,621 patent/US11834505B2/en active Active
- 2020-08-05 IL IL276515A patent/IL276515A/en unknown
-
2022
- 2022-06-07 JP JP2022092210A patent/JP2022120008A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022120008A (en) | 2022-08-17 |
US11834505B2 (en) | 2023-12-05 |
US20200277380A1 (en) | 2020-09-03 |
JP7148414B2 (en) | 2022-10-05 |
EP3478723A4 (en) | 2020-07-29 |
BR112018076684A2 (en) | 2019-04-02 |
EP3478723A2 (en) | 2019-05-08 |
WO2018005682A3 (en) | 2018-02-08 |
MX2018016183A (en) | 2019-06-10 |
IL263611B (en) | 2020-08-31 |
SG10202100100UA (en) | 2021-02-25 |
WO2018005682A2 (en) | 2018-01-04 |
US10590199B2 (en) | 2020-03-17 |
RU2749109C2 (en) | 2021-06-04 |
IL276515A (en) | 2020-09-30 |
KR20220004763A (en) | 2022-01-11 |
CN109641960A (en) | 2019-04-16 |
US20180002424A1 (en) | 2018-01-04 |
RU2019102009A3 (en) | 2020-12-14 |
KR102422411B1 (en) | 2022-07-18 |
IL263611A (en) | 2019-01-31 |
CA3027204A1 (en) | 2018-01-04 |
KR20190028716A (en) | 2019-03-19 |
JP2019532013A (en) | 2019-11-07 |
AU2017290709A1 (en) | 2019-01-24 |
RU2019102009A (en) | 2020-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201807982UA (en) | Substituted inhibitors of menin-mll and methods of use | |
SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
SG11201805420SA (en) | Antibodies and conjugates thereof | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201903835WA (en) | Antibodies directed against programmed death- 1 (pd-1) | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201809751XA (en) | Egfr inhibitor compounds |